Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -145.21M | -118.93M | -80.77M | -54.80M | -40.68M |
| Total Depreciation and Amortization | 1.74M | 1.69M | 749.00K | 719.80K | 695.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.00M | 4.44M | 5.86M | 3.26M | 871.10K |
| Change in Net Operating Assets | -1.31M | -3.78M | -6.30M | -13.61M | -9.59M |
| Cash from Operations | -139.78M | -116.59M | -80.46M | -64.43M | -48.70M |
| Capital Expenditure | -342.80K | -519.80K | -628.80K | -496.60K | -496.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -120.20M | -205.08M | 59.23M | -173.56M | -73.14M |
| Cash from Investing | -120.55M | -205.60M | 58.60M | -174.06M | -73.64M |
| Total Debt Issued | 73.02M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 342.00K | 52.78M | 83.80M | 83.71M | 534.99M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.80K | -1.47M | -4.22M | -4.31M | -4.31M |
| Cash from Financing | 73.46M | 51.31M | 79.58M | 79.39M | 530.68M |
| Foreign Exchange rate Adjustments | -6.50K | 127.50K | -231.60K | 98.80K | -28.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.87M | -270.74M | 57.49M | -159.00M | 408.31M |